TY - JOUR T1 - Trait mindfulness is associated with less amyloid, tau, and cognitive decline in individuals at risk for Alzheimer’s disease JF - medRxiv DO - 10.1101/2021.05.17.21257320 SP - 2021.05.17.21257320 AU - Cherie Strikwerda-Brown AU - Hazal Ozlen AU - Alexa Pichet Binette AU - Marianne Chapleau AU - Natalie L. Marchant AU - John C. S. Breitner AU - Sylvia Villeneuve AU - for the PREVENT-AD Research Group Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/12/2021.05.17.21257320.abstract N2 - BACKGROUND AND OBJECTIVES Mindfulness, defined as non-judgmental awareness of the present moment, has been associated with an array of mental and physical health benefits, including improved cognitive functioning and changes to brain structure and function. Mindfulness may also represent a protective factor for Alzheimer’s disease (AD). Here, we tested the potential protective effect of trait mindfulness on cognitive decline and AD pathology in older adults at risk for AD dementia.METHODS Two hundred sixty-one nondemented older adults with a family history of AD dementia were included from the PREVENT-AD observational cohort study, including 124 with Aβ- and tau-positron emission tomography (PET) scans. All participants completed measures of trait mindfulness and longitudinal cognitive assessments. Multivariate partial least squares analyses were used to examine relationships between combinations of different facets of trait mindfulness and (1) cognitive decline, (2) Aβ, and (3) tau.RESULTS Higher levels of mindful nonjudgment, describing, and nonreactivity were associated with less cognitive decline in attention, global cognition, and immediate and delayed memory. Higher levels of mindful nonjudgment and nonreactivity were related to less Aβ-PET signal in bilateral medial and lateral temporoparietal and frontal regions. Higher levels of mindful acting with awareness, describing, nonjudgment, and nonreactivity were associated with less tau-PET signal in bilateral temporal regions, namely entorhinal cortex, amygdala, and parahippocampal, fusiform, and inferior temporal gyri. These relationships remained significant when additional demographic (age, sex, education and APOE status) and psychological (personality traits and neuropsychiatric symptoms) were included in analyses. When mindfulness, personality traits, and neuropsychiatric symptoms were entered into the same model, mindful nonjudgment showed the strongest association with cognitive decline and Aβ.DISCUSSION Trait mindfulness is associated with less cognitive decline and less Aβ and tau in the brain in older adults at risk for AD dementia. In addition to its other health benefits, trait mindfulness may also represent a psychological protective factor for AD dementia. Longitudinal studies examining the temporal relationship between trait mindfulness and AD markers, along with mindfulness intervention studies with cognition and pathology as outcome variables, will be important for further clarifying the potential protective benefits of mindfulness on AD risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Canada Research Chair, a Canadian Institutes of Health Research Foundation Grant, a Canada Fund for InnovationGrant, and an Alzheimer's Association Grant (to SV). PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public-private partnership using funds provided by McGill University, the Fonds de Recherche du Quebec-Sante, an unrestricted research grant from Pfizer Canada, the Levesque Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for InnovationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board at McGill UniversityAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be released upon reasonable request ER -